Abstract
Aim: To evaluate whether PCR-reverse sequence-specific oligonucleotide can examine the concordance between liquid biopsy and metastatic lesions with acquired resistance. Materials & methods: We examined acquired mutations in chemoresistant lesions and blood obtained from four patients with RAS wild-type metastatic colorectal cancer who underwent treatment with anti-epidermal growth factor receptor antibodies. Results: In one patient, metastatic lesions harbored diverse acquired mutations in KRAS in all seven metastases; the two acquired mutations were detectable in blood collected after the patient acquired resistance. None of the other patients exhibited liquid biopsy mutations, except one, with a BRAF mutation confirmed in primary tumor and peritoneal dissemination. Conclusion: Liquid biopsy based on PCR-reverse sequence-specific oligonucleotide is a successful procedure for capturing acquired mutations with precise information on the RAS mutational spectrum.
Original language | English |
---|---|
Article number | 20210059 |
Journal | Future Science OA |
Volume | 7 |
Issue number | 10 |
DOIs | |
Publication status | Published - Dec 2021 |
Keywords
- Acquired mutations
- BRAF
- PCR-rSSO
- RAS
- colorectal cancer
- liquid biopsy
ASJC Scopus subject areas
- Biotechnology